Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Observational × remimazolam × Clear all

Status

Sponsor Class

Study Type

Interventional 2 Observational 1

Sponsor

Conditions

Interventions

Surveys and Questionnaires 249 Blood Specimen Collection 132 Gene Expression Profiling 88 Interviews as Topic 76 Immunohistochemistry 71 Polymerase Chain Reaction 57 Surgical Procedures, Operative 54 Microarray Analysis 50 Magnetic Resonance Spectroscopy 50 Radiotherapy 45 Flow Cytometry 45 Amplified Fragment Length Polymorphism Analysis 42 Drug Therapy 41 Observation 37 Biopsy 36 Reverse Transcriptase Polymerase Chain Reaction 34 Bevacizumab 33 Data Collection 32 Psychiatric Rehabilitation 26 palbociclib 24 Therapeutics 24 Nivolumab 24 Sorafenib 23 In Situ Hybridization, Fluorescence 23 Neoadjuvant Therapy 22 enzalutamide 21 Rituximab 21 Hepatectomy 21 Focus Groups 21 Docetaxel 21

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05025410 2022-04-25

Remimazolam and Remifentanil Without Neuromuscular Blocking Agent

Seoul National University Bundang Hospital

Myofibroma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡